Mezagitamab
- Generic Name
- Mezagitamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2227490-52-8
- Unique Ingredient Identifier
- 0XMR8L9LOL
- Background
Mezagitamab is under investigation in clinical trial NCT04278924 (Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Participants With Persistent/chronic Primary Immune Thrombocytopenia).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 171
- Registration Number
- NCT06722235
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-12-30
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 16
- Registration Number
- NCT05174221
- Locations
- ๐ธ๐ฌ
National University Hospital- Singapore, Singapore, Singapore
๐ฆ๐บCore Research Group, Milton, Queensland, Australia
๐จ๐ณGuangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 27
- Registration Number
- NCT04776018
- Locations
- ๐บ๐ธ
Mayo Clinic Arizona - PPDS, Scottsdale, Arizona, United States
๐บ๐ธMayo Clinic Jacksonville - PPDS, Jacksonville, Florida, United States
๐บ๐ธWeill Cornell Medical Center, New York, New York, United States
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03439280
- Locations
- ๐บ๐ธ
Washington University School of Medicine, Saint Louis, Missouri, United States
๐บ๐ธCity of Hope - Duarte, Duarte, California, United States
๐บ๐ธWeill Cornell Medical Center, Div. of Hematology Medical Oncology, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.